ELICITATION WITHIN EHTA: POTENTIAL EFFICACY OF MELATONIN MEDICATION FOR STEMI PATIENTS WITH DETECTED HIGH RISK OF REPERFUSION VENTRICULAR FIBRILLATION DURING PCI

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21460%2F24%3A00382218" target="_blank" >RIV/68407700:21460/24:00382218 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.14311/CTJ.2024.4.01" target="_blank" >https://doi.org/10.14311/CTJ.2024.4.01</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.14311/CTJ.2024.4.01" target="_blank" >10.14311/CTJ.2024.4.01</a>

Jazyk výsledku

angličtina

Název v původním jazyce

ELICITATION WITHIN EHTA: POTENTIAL EFFICACY OF MELATONIN MEDICATION FOR STEMI PATIENTS WITH DETECTED HIGH RISK OF REPERFUSION VENTRICULAR FIBRILLATION DURING PCI

Popis výsledku v původním jazyce

Patients with acute ST-segment elevation myocardial infarction (STEMI) have a high risk of ventricular fibrillation. The aim of the study is to determine an unknown parameter of the new diagnostic cardiology technology model created within eHTA, effectiveness of intravenous administration of high doses of melatonin (4mg/kg) before/during PCI as protective medication in STEMI patients with a diagnosed by new technology high risk of ventricular fibrillation at reperfusion using expert elicitation. Ten experts took part in the elicitation and filled out prepared questionnaire, which included experimental evidence for antiarrhythmic action of melatonin, including cellular mechanisms. They expressed their opinions on the potential effectiveness of medication using numerical method and also answered questions about the suitability of the dosage, adverse effects and the risk-benefit ratio. Experts' answers to the main research question were weighted based on their experience. Elicitation revealed the effectiveness value of 71.82% for the tested medication. Eighty percent of experts agreed that the dose is adequate, that side effects will be minimal, and that the benefits of such therapy outweigh possible risks. Results of this study will be applied for eHTA of novel diagnostic technology in cardiology and will help its manufacturer to evaluate the clinical effectiveness of the technology, find the right direction to complete the design and development of medical device, achieve optimal efficiency, present the concept and find investors, prepare for clinical evaluation, CE certification and inclusion to reimbursement system.

Název v anglickém jazyce

ELICITATION WITHIN EHTA: POTENTIAL EFFICACY OF MELATONIN MEDICATION FOR STEMI PATIENTS WITH DETECTED HIGH RISK OF REPERFUSION VENTRICULAR FIBRILLATION DURING PCI

Popis výsledku anglicky

Patients with acute ST-segment elevation myocardial infarction (STEMI) have a high risk of ventricular fibrillation. The aim of the study is to determine an unknown parameter of the new diagnostic cardiology technology model created within eHTA, effectiveness of intravenous administration of high doses of melatonin (4mg/kg) before/during PCI as protective medication in STEMI patients with a diagnosed by new technology high risk of ventricular fibrillation at reperfusion using expert elicitation. Ten experts took part in the elicitation and filled out prepared questionnaire, which included experimental evidence for antiarrhythmic action of melatonin, including cellular mechanisms. They expressed their opinions on the potential effectiveness of medication using numerical method and also answered questions about the suitability of the dosage, adverse effects and the risk-benefit ratio. Experts' answers to the main research question were weighted based on their experience. Elicitation revealed the effectiveness value of 71.82% for the tested medication. Eighty percent of experts agreed that the dose is adequate, that side effects will be minimal, and that the benefits of such therapy outweigh possible risks. Results of this study will be applied for eHTA of novel diagnostic technology in cardiology and will help its manufacturer to evaluate the clinical effectiveness of the technology, find the right direction to complete the design and development of medical device, achieve optimal efficiency, present the concept and find investors, prepare for clinical evaluation, CE certification and inclusion to reimbursement system.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30300 - Health sciences

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Lékař a technika – Clinician and Technology

ISSN

0301-5491

e-ISSN

2336-5552

Svazek periodika

54

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

8

Strana od-do

111-118

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-105001137693